Skip to main content

Advertisement

SpringerLink
Log in

Treatment with stiripentol in a patient with primary hyperoxaluria type 1: lesson for the clinical nephrologist

  • Lessons for the Clinical Nephrologist
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649–658

    Article  CAS  Google Scholar 

  2. Stevens JS, Al-Awqati Q (2019) Lactate dehydrogenase 5: identification of a druggable target to reduce oxaluria. J Clin Invest 129:2201–2204

    Article  Google Scholar 

  3. Liebow A et al (2017) An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol 28:494–503

    Article  CAS  Google Scholar 

  4. Sada N, Lee S, Katsu T, Otsuki T, Inoue T (2015) Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347:1362–1367

    Article  CAS  Google Scholar 

  5. Le Dudal M et al (2019) Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J Clin Invest 129:2571–2577

    Article  Google Scholar 

  6. Kempf C et al (2020) Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatr Nephrol 35:1787–1789

    Article  Google Scholar 

  7. Martin-Higueras C, Feldkötter M, Hoppe B (2021) Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 14:442–444

    Article  Google Scholar 

  8. Moya-Garzon MD et al (2021) Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias. J Pers Med 11(2):74

  9. Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145

    Article  Google Scholar 

Download references

Acknowledgements

Development of this manuscript was supported by the Hôpital Necker - Enfants Malades, Paris, France. We would like to thank Joanne Dalton who contributed to the writing of the first draft of this manuscript on behalf of Springer Healthcare Communications, supported by the Hôpital Necker - Enfants Malades, Paris, France according to Good Publication Practice guidelines.

Author information

Authors and Affiliations

  1. Pediatric Nephrology Unit, University Hospital of Lille, Lille, France

    Priscillia Violier

  2. Néphrologie Pédiatrique et Institut Imagine, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015, Paris, France

    Olivia Boyer, Romain Berthaud & Guillaume Dorval

Authors
  1. Priscillia Violier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivia Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Romain Berthaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guillaume Dorval
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PV and OB enrolled and followed the patient, and collected and analyzed patient data. PV wrote the first draft of the manuscript, and OB, RB and GD critically revised and approved the draft. Each author agrees to be personally accountable for the individual’s own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

Corresponding author

Correspondence to Olivia Boyer.

Ethics declarations

Conflict of interest

Olivia Boyer has received consultancy fees from Alnylam Pharmaceuticals and has been involved as a clinical study investigator by Biocodex. The other authors have no conflicts of interest in relation to this article.

Ethical approval

None.

Consent for publication

The authors declare that they have obtained consent from the caregiver of the patient reported in this article for publication of the information about her that appears within this Case Report.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Violier, P., Boyer, O., Berthaud, R. et al. Treatment with stiripentol in a patient with primary hyperoxaluria type 1: lesson for the clinical nephrologist. J Nephrol 35, 1049–1051 (2022). https://doi.org/10.1007/s40620-021-01116-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-021-01116-9

Keywords

Search

Navigation